Learn Center
A schedule of upcoming FDA decision dates for drugs and treatments in development, which can move biotech and pharma stocks sharply.
An FDA calendar tracks upcoming decision dates from the U.S. Food and Drug Administration on drug approvals, along with other significant regulatory milestones like clinical trial results and advisory committee meetings, for companies with treatments in development. Because an FDA approval or rejection can dramatically change the commercial prospects of a drug, and therefore the company developing it, these dates are among the most closely watched, binary, single day catalysts in the entire stock market, particularly for smaller biotech and pharmaceutical companies with a limited number of drugs in their pipeline.
When a company submits a new drug application to the FDA, the agency assigns a target decision date, known as a PDUFA date, by which it aims to complete its review and issue a decision to approve, reject, or request additional information. Ahead of that date, the FDA sometimes convenes an advisory committee of outside experts to review the data and vote on a recommendation, which the agency is not required to follow but frequently does. An FDA calendar aggregates these known and estimated dates across many companies and drugs into a single trackable schedule.
The EZPZ FDA calendar page lists upcoming decision and advisory committee dates by company and drug, letting you see what regulatory catalysts are coming up across the sector. Because the outcome of an FDA decision is fundamentally binary, approval or rejection, and can move a stock by a large percentage in a single session, these dates carry a different kind of risk than a typical earnings report, and options pricing on affected stocks often reflects that elevated uncertainty heading into the date. A delay to a previously announced date is itself sometimes read as a signal, since the FDA extending its review can suggest unresolved questions about the application.
Biotech and pharma focused traders use the FDA calendar as an essential planning tool, since these decision dates represent some of the highest volatility, highest stakes catalysts available in the stock market, whether traded through the underlying stock or options positioned around the binary outcome. Because the outcome is difficult to predict with confidence even with strong clinical data, many traders treat these events as a distinct, higher risk category requiring smaller position sizing than a typical trade. Others avoid holding positions through a decision date entirely, given how sharply a stock can move on the news either way.
